Triple-negative breast cancer, which lacks ER, PgR, and HER2 expression, is known for its aggressive nature and poor prognosis, and requires chemotherapy and targeted treatment (6–10). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.